Accessibility Menu
Barinthus Biotherapeutics Plc logo

Barinthus Biotherapeutics Plc(NASDAQ) VACC

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-96%
5 Year-96%
1 Year-63%
1 Month-19%
N/A
Barinthus Biotherapeutics Plc last closing stock price
MetricPriceDate
Last closeUSD 0.572026-07-28
Barinthus Biotherapeutics Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.96%USD 0.612026-07-21
1 month-18.57%USD 0.702026-06-26
3 month-4.98%USD 0.602026-04-29
Year to date-18.58%USD 0.702025-12-31
1 year-63.23%USD 1.552025-07-28
3 year-75.22%USD 2.302023-07-28
5 year-96.14%USD 14.772021-07-29
Since inception-95.96%USD 14.102021-04-30

Barinthus Biotherapeutics Plc Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$52.31M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Nov 13, 2023

VACC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Barinthus Biotherapeutics Plc

Barinthus develops medicines that help the immune system fight diseases. Its main products target chronic infections, autoimmune conditions, and cancer. These treatments aim to improve life for people with hard-to-treat illnesses.

Lab Bench to Bedside: Products and Services

  • VTP-1000 (Celiac Disease): Immune therapy for celiac disease, using a targeted approach to reduce harmful immune reactions. 0% of 2025 revenue.
  • VTP-300 (Hepatitis B): Immunotherapy for chronic hepatitis B, designed to help the body control the virus. 0% of 2025 revenue.
  • VTP-200 (HPV): Non-surgical treatment for persistent high-risk human papillomavirus infections. 0% of 2025 revenue.
  • VTP-850 (Prostate Cancer): Immunotherapy for recurrent prostate cancer, aiming to boost the body’s own defenses. 0% of 2025 revenue.
  • SNAP-TI Platform: Technology that trains the immune system to tolerate specific triggers, mainly for autoimmune diseases. 0% of 2025 revenue.

Plot Twists: Growth and Expansion

  • 2021: Listed on NASDAQ Global Market after initial public offering.
  • 2023: Changed name from Vaccitech to Barinthus to reflect new focus.
  • 2025: Announced strategic shift to prioritize immune and inflammation therapies, reducing workforce and closing UK site.
  • 2025: Entered merger agreement with Clywedog Therapeutics, a diabetes-focused company, expected to close in 2026.
  • 2025: Presented positive clinical data for VTP-300 and VTP-1000, seeking partners for further development.

Why Barinthus Is a Bit Different

Barinthus uses a proprietary platform to target immune tolerance, aiming for disease-specific treatments. Its approach focuses on restoring balance rather than suppressing the whole immune system. The company holds patents extending into the 2040s, supporting its specialized technology.

Five Things You Need to Know

  • Revenue was $0 in FY2025, down 100% from $15M in FY2024.
  • Net loss was $66.5M in FY2025, up 8.7% from FY2024.
  • Operating expenses fell 15.5% to $71.1M in FY2025.
  • Cash at year-end 2025 was $71.9M, with no debt reported.

Bottom Line

Barinthus has shifted from infectious disease royalties to focus on immune therapies. The company is adapting through restructuring, cost control, and a pending merger to support future development.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

14

CEO

William Enright

Website

vaccitech.co.uk

Headquarters

Oxford, OX4 4GE, GB

VACC Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-63.87%

Return on Capital

0.59%

Return on Assets

-56.74%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$5.90M

EBITDA

-$32.00M

Operating Cash Flow

-$36.44M

Capital Expenditure

-$32.00K

Free Cash Flow

-$36.48M

Cash & ST Invst.

$65.86M

Total Debt

$11.01M

Barinthus Biotherapeutics Plc Performance Analysis

Barinthus Biotherapeutics Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 44,666,41816568.6%
20232023-12-31USD 805,109-98.2%
20242024-12-31USD 14,975,2991760.0%
20252025-12-31USD 0N/A
Barinthus Biotherapeutics Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Barinthus Biotherapeutics Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.14N/A
20232023-12-31USD -1.92N/A
20242024-12-31USD -1.55-19.0%
20252025-12-31USD -1.645.8%
Barinthus Biotherapeutics Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-6.1%
Q32025-09-3030.8%
Q42025-12-3125.0%
Q12026-03-3148.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

33

N/A

Net Income

-$5.53M

+71.8%

EBITDA

$856.00K

-57.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$65.86M

-33.6%

Total Debt

$11.01M

-7.6%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$9.00M

-9.6%

Short Term Debt

$2.01M

+2.3%

Return on Assets

-56.74%

N/A

Return on Invested Capital

-71.01%

N/A

Free Cash Flow

-$3.37M

+77.4%

Operating Cash Flow

-$3.37M

+77.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
THRXTheseus Pharmaceuticals, Inc.
$4.07+0.12%
SPPISpectrum Pharmaceuticals, Inc.
$1.03-0.49%
ZVRAZevra Therapeutics, Inc.
$9.78+0.51%
TCRTAlaunos Therapeutics, Inc.
$1.90+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOFISoFi Technologies
$15.25-0.09%
INTCIntel
$81.88-0.05%
NVDANvidia
$190.01-0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About VACC

What is the current price of Barinthus Biotherapeutics Plc?

Barinthus Biotherapeutics Plc is trading at N/A per share.

What is the 52-week range for Barinthus Biotherapeutics Plc?

Over the past 52 weeks, Barinthus Biotherapeutics Plc has traded between N/A and N/A.

How much debt does Barinthus Biotherapeutics Plc have?

As of the most recent reporting period, Barinthus Biotherapeutics Plc reported total debt of $11.01M.

How much cash does Barinthus Biotherapeutics Plc have on hand?

Barinthus Biotherapeutics Plc reported $67.19M in cash and cash equivalents in its most recent financial results.

What is Barinthus Biotherapeutics Plc’s dividend yield?

Barinthus Biotherapeutics Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services